金沢大学 薬物動態学研究室

業績

原著論文

2020

1. Kobayashi M., Mizutani A., Nishi K., Muranaka Y., Nishii R., Shikano N., Nakanishi T., Tamai I., Eugenie S. K., Kawai K., [131I] MIBG exports via MRP transporters and inhibition of the MRP transporters improves accumulation of [131I] MIBG in neuroblastoma., Nuclear Medicine and Biology, 90: 49-54 (2020).

2. Liu W., Nakano M., Nakanishi T., Nakajima M., Tamai I., Post-transcriptional regulation of OATP2B1 transporter by a microRNA, miR-24., Drug Metabolism and Pharmacokinetics, 35(6): 515-521 (2020).

3. Hirayama M., Hoshino Y., Yoshii K., Toda R., Kawabata Y., Nakanishi T., Tamai I., Identification of the Uptake Transporter Responsible for Distribution of Acotiamide into Stomach Tissue., Molecular pharmaceutics, 17(4): 1071-1078 (2020).

4. Inagaki M., Nishimura T., Nakanishi T., Shimada H., Noguchi S., Akanuma S. I., Tachikawa M., Hosoya K., Tamai I., Nakashima E., Tomi M., Contribution of prostaglandin transporter OATP2A1/SLCO2A1 to placenta-to-maternal hormone signaling and labor induction., Iscience, 23(5): 101098 (2020).

5. Wada S., Matsunaga N., Tamai I., Mathematical modeling analysis of hepatic uric acid disposition using human sandwich-cultured hepatocytes., Drug Metabolism and Pharmacokinetics, 35(5): 432-440 (2020).

6. Arakawa H., Amezawa N., Kawakatsu Y., Tamai I., Renal Reabsorptive Transport of Uric Acid Precursor Xanthine by URAT1 and GLUT9., Biological and Pharmaceutical Bulletin, 43(11): 1792-1798 (2020).

7. Nakanishi T., Sakiyama S., Takashima H., Honda R., Shumba M. N., Nakamura Y., Kasahara K., Tamai I., Toxicological implication of prostaglandin transporter SLCO2A1 inhibition by cigarette smoke in exacerbation of lung inflammation., Toxicology and Applied Pharmacology, 405: 115201 (2020).

2019, 2018, 2017, 2016, 2015, 2014, 2013,

2012, 2011, 2010, 2009, 2008

総説・著書

英文/English

和文/Japanese

2018 International Meeting on 22nd MDO and 33rd JSSX

第39回生体膜と薬物の相互作用シンポジウム

薬物動態学研究室
〒920-1192
石川県金沢市角間町